GlassScriptPhysician profile
Mahmood Nasir
NPI 1497738934
$4,911.31
in general payments reported to CMS, 2019-2025
21 companies · $516 in 2025
The $516 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $626 · 2020: $614 · 2021: $976 · 2022: $1,139 · 2023: $661 · 2024: $379 · 2025: $516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,555.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,555.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $929.12 | 2019-2025 | Belbuca, Xtampza |
| Amgen INC. | $587.15 | 2019-2023 | Aimovig |
| Lilly USA, LLC | $541.41 | 2019-2023 | Emgality, Reyvow |
| Scilex Pharmaceuticals INC. | $523.89 | 2019-2024 | Ztlido |
| Teva Pharmaceuticals USA, INC. | $436.02 | 2019-2023 | Ajovy, Austedo Xr |
| Abbvie INC. | $405.85 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $212.62 | 2019-2021 | |
| Biodelivery Sciences International, INC. | $206.25 | 2019-2021 | |
| Pfizer INC. | $198.75 | 2019-2025 | |
| Biohaven Pharmaceuticals, INC. | $184.82 | 2021 | |
| Protega Pharmaceutials INC | $163.68 | 2022-2023 | Roxybond |
| Biohaven Pharmaceutical Holding Company LTD. | $155.02 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $90.75 | 2024-2025 | Relistor |
| Forte Bio-Pharma LLC | $78.42 | 2021 | |
| Lundbeck LLC | $59.46 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Upsher-Smith Laboratories LLC | $44.31 | 2019 | |
| Ibsa Pharma INC. | $25.45 | 2020-2021 | |
| Allergan, INC. | $24.16 | 2020 | |
| Daiichi Sankyo INC. | $18.68 | 2019 | |
| Alexion Pharmaceuticals, INC. | $13.37 | 2019 | |
| Supernus Pharmaceuticals, INC. | $12.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mahmood Nasir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.